-+ 0.00%
-+ 0.00%
-+ 0.00%

Opko Health presents preclinical data for weekly acromegaly drug candidate OPK8801001 at ENDO 2026

PUBT·06/15/2026 12:01:40
Listen to the news
Opko Health presents preclinical data for weekly acromegaly drug candidate OPK8801001 at ENDO 2026
  • Opko Health presented preclinical results for OPK8801001 in acromegaly at ENDO 2026.
  • Data showed sustained suppression of a key disease marker, supporting a potential once-weekly option versus daily therapy.
  • Lab findings indicated stronger receptor-blocking activity than an established treatment, positioning OPK8801001 as a differentiated candidate.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opko Health Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606150800PRIMZONEFULLFEED9746388) on June 15, 2026, and is solely responsible for the information contained therein.